Published in World J Gastrointest Pathophysiol on November 15, 2015
Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol (2016) 1.39
MK2: an unrecognized regulator of tumor promoting macrophages in colorectal cancer? Macrophage (Houst) (2016) 0.75
Colitis Is Effectively Ameliorated by (±)-8-Acetonyl-dihydrocoptisine via the XBP1-NF-κB Pathway. Front Pharmacol (2017) 0.75
Effects of indigo naturalis on colonic mucosal injuries and inflammation in rats with dextran sodium sulphate-induced ulcerative colitis. Exp Ther Med (2017) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Genetics and pathogenesis of inflammatory bowel disease. Nature (2011) 7.79
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Inflammatory bowel disease: cause and immunobiology. Lancet (2007) 6.07
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med (2012) 5.80
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2013) 3.83
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med (2005) 3.56
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2013) 3.35
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut (2005) 3.31
Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol (1997) 3.24
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2007) 3.20
Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med (2000) 2.93
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet (2014) 2.61
Biological therapies for inflammatory bowel diseases. Gastroenterology (2009) 2.18
Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol (1994) 2.09
Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med (2014) 2.04
Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology (2004) 1.97
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med (2003) 1.90
Natalizumab and PML. Nat Neurosci (2005) 1.85
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.78
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut (2012) 1.73
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther (2009) 1.73
Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol (2006) 1.45
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther (2005) 1.45
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs (2010) 1.39
New pathophysiological insights and modern treatment of IBD. J Gastroenterol (2010) 1.31
Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun (2010) 1.29
Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol Int (2002) 1.12
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol (2014) 1.09
Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis (2012) 1.05
Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol (2013) 0.97
Treat the patient or treat the disease? Dig Dis (2012) 0.93
Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis (2008) 0.84
Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol (2008) 0.77